Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 4/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169429 | 1.00 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL24807718 | 0.85 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL30146559 | 0.85 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL23601039 | 0.85 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL29909941 | 0.83 | ABCG2 (0.31) | — | |
| SCHEMBL24806326 | 0.83 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL30146525 | 0.83 | PTGES (0.36) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL30095528 | 0.81 | MAT2A (0.54) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL24808393 | 0.81 | MAT2A (0.54) | PTGESTBXAS1CSNK2A2CSNK2BMAT2A | |
| SCHEMBL29909728 | 0.81 | ABCG2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PTGES 1780/4885TBXAS1 849/4885CSNK2A2 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.